Asset profile
RAP-219
Small molecule
Evidence outlook · registrational
Epilepsy: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2029-07.
NCT06377930: The study enrolled 30 participants in a single, open-label RAP-219 group without randomization or a placebo/active comparator, relying on within-participant baseline comparisons for the clinical seizure endpoint. Because no trial results are posted, whether the primary endpoint was met is unknown, and the uncontrolled design provides weak evidence.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
February 2028 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2029 (2)
July 2029 (2)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchWhat to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.